Pernix Therapeutics Holdings is a pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, primarily for the U.S. market. Co. targets therapeutic areas such as central nervous system, including pain, psychiatry and neurology. Co.'s branded products include: Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor (doxepin), non-narcotic, non-scheduled and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet (sumatriptan/naproxen sodium), a medication indicated for the acute treatment of migraine pain and inflammation. We show 10 historical shares outstanding datapoints in our coverage of PTX's shares outstanding history.
Understanding the changing numbers of PTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PTX by allowing them to research PTX shares outstanding history
as well as any other stock in our coverage universe. |
Free PTX Email Alerts:
Video: Shares Outstanding Importance
